| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $24.4M | -44.5% |
| SG&A Expense | $30.8M | +65.2% |
| Operating Income | -$55.2M | +11.9% |
| Pre-tax Income | -$52.4M | +13.5% |
| Income Tax | $0 | — |
| Net Income | -$52.4M | +13.2% |
| EPS (Basic) | -$0.60 | +71.3% |
| EPS (Diluted) | -$0.60 | +71.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $176.5M | +76.9% |
| Current Assets | $178.7M | +77.2% |
| Total Assets | $179.5M | +78.0% |
| Current Liabilities | $19.5M | -3.9% |
| Total Liabilities | $19.5M | -8.4% |
| Stockholders' Equity | $146.8M | +147.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$28.1M | -86.5% |
| Capital Expenditures | $75K | — |
| Investing Cash Flow | -$5.1M | +36.6% |
| Financing Cash Flow | $109.8M | -9.4% |
| Free Cash Flow | -$28.2M | — |